A US FDA inspector can now walk into your plant without informing you. In FY 2026, 87% of the FDA India office inspections were unannounced, up from 47% the year before. Because of that one change, the risk in inspection for Indian drug manufacturers is vastly different. It’s not okay to wait for a notice letter and then spend 2 weeks preparing the plant. If the inspector visits on a regular Tuesday, then what he sees on that day is what counts.
That is why FDA inspection readiness in India needs to be part of your daily work, not a task you start when an inspection is near. There is a good side to this, though. A few issues are consistently mentioned in most FDA warning letters. These issues can easily be identified in your records before an inspector. A missed audit trail review. A weak investigation. A training gap. A record that does not match what happened on the floor. Sometimes your own data can provide the clues to where the trouble lies.
This guide will help you know what to look for, which records to review, and what you can do to address gaps in a timely and manageable fashion. The mission is to identify the problems before the FDA does.
Why FDA Inspection Readiness in India Needs a New Approach
The FDA has changed how it checks plants outside the United States. Those changes reshape FDA inspection readiness in India for every site that ships medicines to US patients. This means that inspection readiness for the US export market shouldn’t be a ‘last-minute job’ for any Indian company. In March 2022, the FDA started conducting unannounced inspections in India. By May 2024, 94 of its 114 pilot inspections were unannounced, according to NSF.
The answer is simple: You might need to see how a plant functions during the day. Even when plants in the United States were given a heads-up, the FDA has discovered serious issues more than twice as many times at foreign plants as at U.S. plants. FDA enforcement is also rising. Drug warning letters increased from 190 in FY 2024 to 303 in FY 2025—a 59% jump.
For Indian pharma plants, the message is clear: be ready every day, not just when an FDA inspection is announced.
Where Hidden Inspection Risks Usually Sit
The majority of FDA inspection issues are not caused by a single failure. They build up through small gaps that teams miss or ignore.
Start with these five areas:
- Data integrity: Missing audit trails, shared logins, or unexplained test results can raise serious concerns.
- Documentation: Late entries, copies, or unchecked signatures will quickly get noticed.
- Quality systems: Open CAPA, repeat deviations, and poor root cause reviews indicate that problems can be out of control.
- Lab controls: If there is no clear reason for repeated OOS testings, tough questions will be asked.
- Vendor oversight: Ineffective controls over vendors and contract labs can be your compliance issue as well.
Many sites also overlook how small gaps connect with each other. A late batch entry may look minor on its own. Combined with a shared login, it tells inspectors that your controls are weak.
Data integrity deserves extra focus for any site that exports to the United States. The FDA Group data shows integrity problems in roughly 60% of warning letters to Indian sites. Certainty Software reviewed these findings in a recent report on warning letters.
A Practical Method to Find Risks Before the Investigator Does
There doesn’t have to be a large budget to identify inspection risks. You must have a clear procedure and people willing to give an in-depth look.
These five steps help any site build FDA inspection readiness in India.
- Map your risks: List the products you ship to the US and the key processes behind them. Prioritize them based on the risk to the patients and past problems.
- Review history: Past 3 years of internal audits, deviations, complaints, and recalls. Be aware of recurring problems. They often point to weak controls.
- Walk the floor: Go to the plant, lab, and warehouse without prior warning to the team. Observe staff and ask what they do, then ask if it corresponds with the records.
- Trace the data: Select 10 batches and follow each batch all the way back from the raw data to the final certificate. Monitor audit trails, user access, and changes or deletions.
- Record each gap: Assign risk level, owner & due date to each finding. Check open items monthly to prevent them from being overlooked.
This review can be performed by a small team of members from QA, production, and lab. Different teams notice different problems.
Quick Checks for Your Team
| Risk area | Warning sign | Quick check |
| Data integrity | Shared logins | Review user access |
| Documentation | Late entries | Compare batch and equipment logs |
| CAPA | Repeat deviations | Check for weak root cause work |
| Vendor control | No recent audit | Check the last audit date |
Why a Mock FDA Inspection Gives the Clearest Picture
Internal reviews are helpful, but it is hard to see the issues in your own system. An outside team can see what your team might be missing and introduce an extra layer of stress.
NSF recommends starting inspection readiness about 12 months before an expected FDA visit. It also recommends a simulated inspection up to six months prior to inspection, preferably by former regulators. With unannounced visits now more common, these timelines should be seen as a minimum.
A good mock inspection should feel like the real thing. The team should practice handling document requests, managing front-room and back-room roles, and answering tough questions. It also shows how people respond when they are under pressure.
After the mock inspection, ask for a written report. Each finding should have a risk level and a clear action to fix it. How your team behaves during an inspection matters too. One FDA warning letter involved an Indian company that claimed workers were on strike to delay an inspection. The FDA found that the plant was still making products.
Never block, delay, or limit an FDA inspection. It can turn a compliance issue into a much bigger problem.
Mistakes That Hide Real Risks
Even careful teams make errors when they build FDA inspection readiness in India on their own. Knowing the common ones helps you avoid repeating them in your own audits.
The first mistake is cleaning up records just before an audit. Inspectors compare dates, signatures, and system logs, so late changes often create new questions. A second mistake is reviewing only paperwork, while real risks often appear in how operators perform tasks.
The third mistake is treating small deviations as isolated events. Several minor issues in one area can point to a weak system and raise FDA inspection risks. Finally, many teams forget to review contract partners, whose gaps can become your inspection findings.
How to Keep Inspection Readiness Going All Year
Risk identification isn’t a one-off process. Plants change, people leave, and new products come in. Regular checks help keep FDA inspection readiness in India on track.
- Run monthly self-inspections: Check a different department each month and share the findings with the team.
- Keep staff trained: Refresh training on GMP, CAPA, and how to handle questions from FDA inspectors.
- Implement corrective actions on Form 483: Respond on time; provide clear evidence to support each corrective action.
Conclusion
Indian pharma companies cannot predict every question an FDA investigator may ask. They can recognize weak controls before they are presented with such questions.
A combination of quality-system review, data checks, employee interviews, trend analysis, mock inspections, and CAPA follow-up is best. Recent FDA actions with Indian facilities demonstrate that data integrity and quality control continue to be a regulatory concern.
For companies serving the US market, inspection readiness should remain an operating discipline rather than an emergency project. XFDA Pharma Advisors can identify inspection risks through independent assessments and mock FDA inspections.
Talk to XFDA Pharma Advisors for real-world FDA inspection readiness assistance prior to regulators visiting your site.
FAQs
What does the FDA look for during an inspection in India?
Inspectors check cGMP compliance, data integrity, and quality systems across the whole site. They compare written records with what actually happens on the production floor.
How often does the FDA inspect pharma plants in India?
There is no fixed schedule, because the FDA selects sites by risk. It carried out 155 inspections in India during 2023, including routine and for-cause visits.
How long do you have to respond to an FDA Form 483?
The FDA expects a written response within 15 working days. Weak or late replies can lead to a warning letter.
Can the FDA inspect Indian plants without notice?
Yes, the FDA can inspect without notice, and it expanded unannounced foreign inspections in May 2025. That means every site should stay ready each day of the year.
What is a mock FDA inspection?
It is a practice audit run like a real inspection. It shows hidden gaps in records, systems, and staff responses before the FDA finds them.





